Michael Weening - Jun 2, 2025 Form 4 Insider Report for CALIX, INC ((CALX))

Signature
/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening
Stock symbol
(CALX)
Transactions as of
Jun 2, 2025
Transactions value $
-$4,029,310
Form type
4
Date filed
6/3/2025, 04:25 PM
Previous filing
Feb 18, 2025
Next filing
Jul 24, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Weening Michael President & CEO, Director C/O CALIX, INC., 2777 ORCHARD PARKWAY, SAN JOSE /s/ Tom Gemetti as Attorney-in-Fact for Michael Weening 2025-06-03 0001678385

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction (CALX) Common Stock Options Exercise $510K +80K +505.94% $6.38 95.8K Jun 2, 2025 Direct
transaction (CALX) Common Stock Options Exercise $119K +20K +20.87% $5.95 116K Jun 2, 2025 Direct
transaction (CALX) Common Stock Sale -$4.66M -100K -86.35% $46.59 15.8K Jun 2, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction (CALX) Stock Option (right to buy) Options Exercise $0 -80K -100% $0.00 0 Jun 2, 2025 Common Stock 80K $6.38 Direct F2
transaction (CALX) Stock Option (right to buy) Options Exercise $0 -20K -9.8% $0.00 184K Jun 2, 2025 Common Stock 20K $5.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.025 to $47.005, inclusive. Full information on the number of shares sold at each sale price is available upon request.
F2 100% of the shares subject to the option were fully vested and exercisable on June 27, 2020.
F3 100% of the shares subject to the option were fully vested and exercisable on January 1, 2021.

Remarks:

Sales reported on the Form 4 were effected pursuant to a previously established Rule 10b5-1 trading plan.